Roche’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People with ALK-Positive Early-Stage Non-Small Cell Lung Cancer

The study results showed that Alecensa® reduced the risk of disease recurrence or death by 76% compared with platinum-based chemotherapy in people with completely resected stage IB to IIIA ALK-positive NSCLC.